Table 5.
Reported cases of FSGS after COVID-19 vaccination.
| Authors | Age | sex | PMH | Timeline of symptom onset | Type of Vaccine | Begin of symptoms | Laboratory features | treatment | outcome |
|---|---|---|---|---|---|---|---|---|---|
| Jha et al. | 21 | M | N | 12 days after 1st dose | Viral vector | facial puffiness; lower limb swelling | Scr:1.06mg/dl;protein: 4+; ALB:0.9 g/dl; Renal biospy: FSGS | steroid; tacrolimus; rituximab | NR |
| Dormann et al. | 20 | F | Vegan diet | 5 days after 1st dose | mRNA | generalized edema | Scr:0.47 mg/dl;proteinuria; UPCR: 10.3 g/g;ALB: 120 mg/dl; Renal biospy: FSGS | prednisolon;diuretic; lipid-lowering; vitamin D substitution | PR |
| Fenoglio et al. | 24 | F | N | after 2nd dose | mRNA | NS | Renal biospy: FSGS | Glucocorticoids | NA |
| Lim et al. | 29 | M | N | 7 days after 1st dose | mRNA | edema; decreased urine output | Scr:1.24mg/dL; protein:4+; ALB:2.5g/dL; UPCR: 6.12 g/g; C3:144mg/dL;C4:65 mg/dL Renal biospy: FSGS | prednisolone; diuretics; angiotensin receptor blocker;statin | R |
| Marega et al. | 80 | F | TTP;HT; HTP;IHD | 2 wk after 2nd dose | mRNA | weight increased; generalized edema | Scr :2 mg/dL;ALB: 2 g/dL proteinuria :300 mg/dL;MH; PLA2R Ab:Positive; kidney biopsy :FSGS superimposed on MN | Steroids; cyclophosphamide | R |
F, female; M, male; focal segmental glomerulosclerosis, FSGS; IHD,ischemic heart disease;TTP, thrombotic thrombocytopenic purpura; HT, hypothyroidism;HTP, hypertension;MH,Microscopic hematuria;NS, nephrotic syndrome; PLA2R,phospholipase A2 receptor; Scr, Serum creatinine; ALB, serum albumin; UPCR,urine protein-to-creatinine ratio;C3, complement C3; C4, complement C4; N,none; R,remission; PR, partial remission; NA, non-applicable; NR, no response.